Sanofi | SNY - Gross Profit On Sales




Sanofi reported EUR10.07B in Gross Profit on Sales for its fiscal quarter ending in September of 2024.

Gross Profit On Sales Change Date
AbbVie USD 10.71B 458M Dec/2024
Amgen USD 5.97B 781M Dec/2024
AstraZeneca USD 12.17B 1.06B Dec/2024
Bristol-Myers Squibb USD 7.53B 1.4B Dec/2024
Canopy Growth CAD 21.84M 1.19M Sep/2024
Corcept Therapeutics USD 179.68M 18.41M Sep/2024
Drreddys Laboratories INR 47.77B 1.42B Sep/2024
Eli Lilly USD 11.13B 10.16B Dec/2024
Galapagos EUR -37430000 97.26M Dec/2024
Genmab DKK 6.1B 837M Dec/2024
GlaxoSmithKline GBP 5.56B 57M Dec/2024
Glaxosmithkline GBP 5.68B 143M Sep/2024
Indivior 248M 1000K Sep/2024
J&J USD 15.58B 69M Dec/2024
Merck USD 11.8B 1.61B Dec/2024
Novartis USD 10.23B 294M Dec/2024
Novartis USD 9.93B 228M Sep/2024
Pacira USD -143466000 275.31M Sep/2024
Perrigo USD 404.4M 9.7M Sep/2024
Pfizer USD 12.02B 418M Dec/2024
Prestige Brands USD 161.05M 3.67M Dec/2024
Roche Holding CHF 11.69B 48M Dec/2024
Sanofi EUR 10.07B 2.1B Sep/2024
Sanofi EUR 10.07B 2.1B Sep/2024
Supernus Pharmaceuticals USD 38.5M 111.91M Sep/2024
UCB EUR 970M 788M Jun/2024
Zoetis USD 1.61B 928M Dec/2024